Paradigm Biopharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Paradigm Biopharmaceuticals Ltd: Type D Response Submitted and Received by the US FDA
Paradigm Biopharmaceuticals Ltd: PAR to present at NWR Healthcare Conference
Paradigm Biopharmaceuticals Ltd: Change of Director's Interest Notice
Paradigm Biopharmaceuticals Ltd: Change of Director's Interest Notice
Paradigm Biopharmaceuticals Ltd: Final Director's Interest Notice
Paradigm Biopharmaceuticals Ltd: Initial Director's Interest Notice
Paradigm Biopharmaceuticals Ltd: PAR Employee Performance Rights Plan Issue
Paradigm Biopharmaceuticals Ltd: PAR Appoints Business Development Consultant
Paradigm Biopharmaceuticals Ltd: Primary Endpoint Achieved in Phase 2 MPS VI Trial
Paradigm Biopharmaceuticals Ltd: Paradigm Receives $7.36m R&D Tax Incentive Refund
Paradigm Biopharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Paradigm Biopharmaceuticals Ltd: PAR Selected for Major OA Conference Presentations
Paradigm Biopharmaceuticals Ltd: Notice of release of escrowed securities
Paradigm Biopharmaceuticals Ltd: Change of Director's Interest Notice - Fisher
Paradigm Biopharmaceuticals Ltd: Change of Director's Interest Notice - Rennie
Paradigm Biopharmaceuticals Ltd: 2023 AGM Chairman Address
Paradigm Biopharmaceuticals Ltd: Security Class Reinstatement to Quotation PARO
Paradigm Biopharmaceuticals Ltd: Listing of Options - Top 20 Holders and Distribution Reports
Paradigm Biopharmaceuticals Ltd: Security Class Suspension from Quotation PARO
No Data